New York State Teachers Retirement System Raises Stock Holdings in IQVIA Holdings Inc. $IQV

New York State Teachers Retirement System increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,060 shares of the medical research company’s stock after purchasing an additional 3,349 shares during the period. New York State Teachers Retirement System owned 0.08% of IQVIA worth $30,218,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of IQV. Boston Partners purchased a new stake in shares of IQVIA in the third quarter worth $676,698,000. AQR Capital Management LLC grew its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Citigroup Inc. grew its stake in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after acquiring an additional 475,557 shares during the last quarter. Cantillon Capital Management LLC grew its stake in shares of IQVIA by 27.3% in the third quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after acquiring an additional 413,256 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on IQV shares. BMO Capital Markets set a $250.00 price objective on IQVIA in a research report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Tuesday, April 21st. Morgan Stanley set a $240.00 price objective on IQVIA in a research report on Wednesday, February 11th. Finally, UBS Group dropped their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Buy” and a consensus target price of $226.63.

IQVIA Stock Down 0.4%

NYSE IQV opened at $157.73 on Friday. The stock’s 50-day moving average price is $169.36 and its 200-day moving average price is $201.57. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a market capitalization of $26.77 billion, a P/E ratio of 20.07, a price-to-earnings-growth ratio of 1.58 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter last year, the company earned $3.12 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.